165 results
6-K
EX-99.3
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
or allogeneic transplantation in cancer patients. Clinical data has demonstrated the ability of motixafortide to mobilize higher numbers of long-term engrafting
6-K
EX-99.2
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
-CURRENT LIABILITIES
Long-term loan, net of current maturities
Lease liabilities
Total non-current liabilities
COMMITMENTS AND CONTINGENT LIABILITIES … CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 5 – LONG-TERM LOAN
In September 2022, the Company entered into a $40 million loan agreement
6-K
EX-99.1
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
Current maturities of long-term loan
Contract liabilities
Accounts payable and accruals:
Trade
Other
Current maturities of lease liabilities
Warrants …
Total current liabilities
NON-CURRENT LIABILITIES
Long-term loan, net of current maturities
Lease liabilities
Total non-current liabilities
COMMITMENTS
6-K
EX-99.1
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
with the APHEXDA launch and advancing key life cycle programs for long-term growth opportunities”, said Philip Serlin, Chief Executive Officer of BioLineRx
424B5
BLRX
Bioline Rx Ltd
1 Apr 24
Prospectus supplement for primary offering
10:30am
incorporated by reference herein and the accompanying prospectus.
As of December 31, 2023
Actual
As Adjusted
Non-Current Liabilities:
Warrants
Long-term loan … , except share
data)
Non-Current Liabilities:
Warrants
Long-term loan, net of current maturities
Lease liabilities
Total non-current liabilities
20-F/A
bn9i e11kw
26 Mar 24
Annual report (foreign) (amended)
4:57pm
6-K
EX-99
6g7xfuz 71okk
26 Mar 24
BioLineRx Reports 2023 Financial Results and Recent Corporate
7:06am
F-3
qqdxys3
29 Dec 23
Shelf registration (foreign)
4:15pm
6-K
EX-99
jmo96vh1 z8
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
ed66s 0mj
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
z7752e8v
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
km0o 8n381
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
7bkh3 y1w
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm
6-K
EX-99
2qvdmh3
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
enkfq0o01jq sjeh
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
vvla18bsrgg 7p
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-99
z4isiy 90jxgvy7o
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-99
h3icbtqpnjdnx829vg1f
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-99
l8jvr66q2jb7yz1gthm
3 Nov 22
BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma
9:20am